Compare LFS & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFS | CING |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | Japan | United States |
| Employees | 1055 | 14 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.2M | 64.5M |
| IPO Year | N/A | N/A |
| Metric | LFS | CING |
|---|---|---|
| Price | $2.32 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | ★ 722.6K | 168.9K |
| Earning Date | 04-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $3.16 |
| 52 Week High | $12.49 | $11.89 |
| Indicator | LFS | CING |
|---|---|---|
| Relative Strength Index (RSI) | 57.89 | 57.73 |
| Support Level | $2.16 | $4.80 |
| Resistance Level | $2.74 | $5.15 |
| Average True Range (ATR) | 0.30 | 0.28 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 18.78 | 94.15 |
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children. The company focuses on covering 13 sports like soccer, basketball, and dance and in child athletic development, club activity management for schools, and social businesses like elderly care.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.